Related Experiment Video

Updated: Sep 27, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
07:45

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice

Published on: October 25, 2024

Pat Price discusses the potential of molecular imaging for drug development. Interview by Joanna Owens

Pat Price

    Drug Discovery Today
    |March 14, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
    09:08

    Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

    Published on: December 20, 2024

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
    09:06

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

    Published on: February 3, 2023

    Related Experiment Videos

    Last Updated: Sep 27, 2026

    Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
    07:45

    Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice

    Published on: October 25, 2024

    Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
    09:08

    Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

    Published on: December 20, 2024

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
    09:06

    Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

    Published on: February 3, 2023

    Related Concept Videos

    Positron Emission Tomography01:29

    Positron Emission Tomography

    Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
    One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

    Articles linked to this work by shared authors, journal, and citation graph.

    The UK's radiotherapy workforce shortage: Reforming regulation to address the gap.

    European journal of cancer (Oxford, England : 1990)·2026

    NHS cancer services and systems-ten pressure points a UK cancer control plan needs to address.

    The Lancet. Oncology·2024

    The impact of transportation mode, socioeconomic deprivation and rurality on travel times to radiotherapy and surgical services for patients with prostate cancer: A national population-based evaluation.

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024

    The future of cancer care in the UK-time for a radical and sustainable National Cancer Plan.

    The Lancet. Oncology·2023

    Total-body imaging: Transforming the role of positron emission tomography.

    Science translational medicine·2017

    Development and experimental medicine applications of PET in oncology: a historical perspective.

    The Lancet. Oncology·2012

    NR4A2: a next-generation drug target orchestrating dynamic gene regulation and protein interactions.

    Drug discovery today·2026

    Patient access to cell and gene therapies in Europe: stakeholder perspectives on impeding factors across the medicine lifecycle.

    Drug discovery today·2026

    AI-integrated iPSC multi-omics: advancing phenotype discovery and drug target identification in rare diseases.

    Drug discovery today·2026

    Advancing a drug-development program is not the same as de-risking it.

    Drug discovery today·2026

    From artificial intelligence promise to translational practice in drug discovery: Reproducibility, validation and evidence-based implementation.

    Drug discovery today·2026

    The role and mechanism of heat shock proteins in the development of pulmonary arterial hypertension.

    Drug discovery today·2026

    Aspirin in Canada: The First Quarter-Century.

    Canadian journal of health history = Revue canadienne d'histoire de la sante·2026

    Driving Legislative Change for Access to Medications.

    Pediatrics·2026

    When vendor reputation does not matter: Trust decoupling and pragmatic trust in Generative AI adoption among university students.

    Acta psychologica·2026

    The Shape of Medical Devices Regulation in the United Kingdom? Brexit and Beyond.

    Law, technology and humans·2026

    Impact of the 2017 secured-prescription regulation of zolpidem on hypnotic dispensing in France: a nine-year interrupted time-series analysis.

    Sleep medicine·2026

    Awareness and Use of Delta-8-THC Cannabis Products in the United States: Findings from National Surveys in 2021 and 2022.

    Cannabis and cannabinoid research·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us